Education
About Us
Working with TipRanks
Follow Us
Paul Hopper Insider Profile
4 Followers
Paul Hopper, Director at EyePoint Pharmaceuticals, holds 0.00 shares in Scopus BioPharma (Ticker: SCPS), holds 10.00K shares in EyePoint Pharmaceuticals (Ticker: EYPT), holds 0.00 shares in Fibrocell Science (Ticker: FCSC).
Paul Hopper has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul Hopper holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Oct 03, 2012 - Oct 03, 2013
Return:+188.20%
The most profitable trade made by Paul Hopper
Paul Hopper's Trading History
EyePoint Pharmaceuticals
Oct 03, 2012
Director
Informative Buy
16.15K
$154.50K
Scopus BioPharma
Nov 17, 2021
Director
Uninformative Buy
―
―
Fibrocell Science
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see Paul Hopper's performance on stock
You May Also Like
Paul Hopper insider profile FAQ
What is the percentage of profitable transactions made by Paul Hopper?
The percentage of profitable transactions made by Paul Hopper is ―.
What is the average return per transaction made by Paul Hopper?
The average return per transaction made by Paul Hopper is ―.
What stocks does Paul Hopper hold?
Paul Hopper holds: EYPT, SCPS, FCSC stocks.
What was Paul Hopper’s latest transaction?
Paul Hopper latest transaction was an Uninformative Buy of ―.
What was Paul Hopper's most profitable transaction?
Paul Hopper’s most profitable transaction was an Informative Buy of EYPT stock on October 3, 2012. The return on the trade was 188.20%.
What is Paul Hopper's role in EyePoint Pharmaceuticals?
Paul Hopper's role in EyePoint Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.